"instanceType","uuid:ID","rationale","id","versionIdentifier"
"StudyVersion","6d7bafea-bd01-46e0-89b2-7461ad046889","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","2"
